CDKN2A promoter methylation is related to the tumor location and histological subtype and associated with Helicobacter pylori flaA(+) strains in gastric adenocarcinomas

Promoter hypermethylation of CDKN2A (p16INK4A protein) is the main mechanism of gene inactivation. However, its association with Helicobacter pylori infection is a controversial issue. Therefore, we examined a series of gastric adenocarcinomas to assess the association between p16INK4A inactivation and H. pylori genotype (vacA, cagA, cagE, virB11 and flaA) according to the location and histological subtype of the tumors. p16INK4A expression and CDKN2A promoter methylation were found in 77 gastric adenocarcinoma samples by immunohistochemistry and methylation-specific PCR, respectively. Helicobacter pylori infection and genotype were determined by PCR. A strong negative correlation between immunostaining and CDKN2A promoter region methylation was found. In diffuse subtype tumors, the inactivation of p16INK4A by promoter methylation was unique in noncardia tumors (p = 0.022). In addition, H. pylori-bearing flaA was associated with non-methylation tumors (p = 0.008) and H. pylori strain bearing cagA or vacAs1m1 genes but without flaA was associated with methylated tumors (p = 0.022 and 0.003, respectively). Inactivation of p16INK4A in intestinal and diffuse subtypes showed distinct carcinogenic pathways, depending on the tumor location. Moreover, the process of methylation of the CDKN2A promoter seems to depend on the H. pylori genotype. The present data suggest that there is a differential influence and relevance of H. pylori genotype in gastric cancer development.

Inactivation of COX-2, HMLH1 and CDKN2A Gene by Promoter Methylation in Gastric Cancer: Relationship with Histological Subtype, Tumor Location and Helicobacter pylori Genotype

Objective: We aimed to evaluate the inactivation of COX-2, HMLH1 and CDKN2A by promoter methylation and its relationship with the infection by different Helicobacter pylori strains in gastric cancer. Methods: DNA extracted from 76 H. pylori-positive gastric tumor samples was available for promoter methylation identification by methylation-specific PCR and H. pylori subtyping by PCR. Immunohistochemistry was used to determine COX-2, p16(INK4A) and HMLH1 expression. Results: A strong negative correlation was found between the expression of these markers and the presence of promoter methylation in their genes. Among cardia tumors, negativity of p16(INK4A) was a significant finding. on the other hand, in noncardia tumors, the histological subtypes had different gene expression patterns. In the intestinal subtype, a significant finding was HMLH1 inactivation by methylation, while in the diffuse subtype, CDKN2A inactivation by methylation was the significant finding. Tumors with methylated COX-2 and HMLH1 genes were associated with H. pylori vac A s1 (p = 0.025 and 0.047, respectively), and the nonmethylated tumors were associated with the presence of the gene flaA. Conclusions: These data suggest that the inactivation of these genes by methylation occurs by distinct pathways according to the histological subtype and tumor location and depends on the H. pylori genotype. Copyright (C) 2011 S. Karger AG, Basel

Desenvolvimento de um escore preditor da eficácia do tratamento quimioterápico pré-operatório em mulheres com carcinoma de mama localmente avançado

Pós-graduação em Ginecologia, Obstetrícia e Mastologia - FMB

Controle de qualidade em radioterapia: dosimetria de fótons em acelerador linear – Mevatron MXT

The treatment of a tumor with ionizing radiation is an ongoing process with well differentiated stages. These ones include the tumor diagnosis and location, the decision on the treatment strategy, the absorbed dose planning and calculation, the treatment administration, the absorbed dose verification and the evaluation of results in short and long terms. The quality of a radiotherapy procedure is closely linked to factors that may be classified as clinical, such as the diagnosis, the tumor location, the treatment strategy chosen and the continuous treatment reassessment; dosimetric or physical, such as the uncertainty in the dose calculation, its optimization and verification, the suitability of the equipment to provide a radiation beam consistent with the treatment planning; finally, others which are related to the practical application of radiotherapy treatment and the handling of the patient. In order to analyze the radiotherapy quality, one should realize that the three aspects (medical, physical or dosimetric and practical application) should be considered in a combined way. This means that numerous actions of the radiotherapists, medical physicists and technicians in radiotherapy should be held jointly and their knowledge level will significantly affect the treatment quality. In this study, the main physical parameters used in dosimetry are defined as well as determined experimentally for a linear accelerator Mevatron - MXT. With this, it is intended to provide recommendations for the physical aspects of Quality Assurance (QA) in the radiotherapy treatments, and these will usually be applied by professionals in Medical Physics. In addition to these instructions, it is recommended that additional texts are prepared to address in detail the clinical aspects of the treatments QA

Modelos de tratamento para adenocarcinomas de próstata tratados por radioterapia conformacional 3D

Radiotherapy is a branch of medical physics related to the treatment of malignant neoplasm, being an important instrument in the fight against cancer, when combined with the effort of a multidisciplinary team, composed of, physicians, physicists, nurses and technicians. Every year more than 3.5 million new cases of cancer are recorded in the world, being the prostate cancer responsible for approximately 25% of this amount (INCA and IARC, 2008). In this type of cancer, radiotherapy is a method indicated for treatement. The technological advance in this area over years has allowed a greater accuracy in the tumor location, more conformation of the radiation beam around the tumor, reducing the dose in healthy tissues and a consequent dose increase on treatment (Bedford et al., 1999). A radiotherapy planning, in which the physicist develops an important role, is composed of several steps, including choosing the best configuration of treatment beams. This choice has a close relationship with success of therapy and is critical to achieve the best distribution of dose inside the tumor and expose the least as possible the healthy tissue to radiation. In this work, two options for setting up camps in the first phase in a treatment of prostate cancer were simulated in computer planning: 4 fields orthogonal or “Box” with gantry angles in 00, 1800, 2700 e 90° and 4 fields angled or “X” (1350, 450, 3150 e 2250). The percentage of the rectal volume exposed to 40, 50, 60, 72 and 76 Gy should be limited to 60, 50, 25, 15 and 5% respectively (Greco et al., 2003). The femoral toxicity have limited dose by 70% of the total dose prescribed in a prostate treatment (Bedford et al., 1999). The planning of 27 patients with prostate adenocarcinoma submitted to 3D conformal radiotherapy were accompanied. As a result, it was assessed that the best TCP (tumor control probability)... (Complete abstract click electronic access below)

Terapia fotodinâmica e luz branca: aspectos analíticos e perspectivas da viabilidade do tratamento

Photodynamic Therapy (PDT) is a technique used to treat several types of lesions, such as cancer, microbial control, and esthetic dentistry cases. The performance of PDT involves the use of a photosensitizer (PS), which mainly will be located in cancer cells and is irradiated with visible light. This process, when it occurs in the presence of oxygen triggers the formation of reactive oxygen species that are cytotoxic to cells. These species cause cell death and subsequent tumor necrosis. The use of white light as a light source for multispectral Photodynamic Therapy and its consequences to the photodynamic effect is not yet completely established, and therefore there is interest in studying the parameters involved for analyzing the best conditions for applying treatment. The wavelength is crucial to improve the therapeutic effect, since both the optical properties of the biological tissue as the PS depend on these parameters. For FS studied in this work (Photogem®) are most often used wavelengths in the red region, due to their larger penetration depth in biological tissue. Thus, the light source becomes a fundamental aspect, their choice depends on the specific application and is based on the tumor location, light dose to be delivered and FS chosen. Despite all the advantages presented by lasers, the fact of having an emission spectrum essentially monochrome makes only one possible transition possible for the absorption of FS is used. Therefore, more extensive light sources such as light emitting diodes (LED), could be better used in some cases the laser, with the additional advantage of a reduced cost. Therefore, the choice of the white LED comes from an emission spectrum that still wider LED colors defined by allowing greater use of the several absorption bands and with varying depths of operation, according to the wavelength... (Complete abstract click electronic access below)

Análise mutacional da região dos exons 5 a 8 do gene supressor de tumor p53 em neoplasias mamárias caninas

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Análise multifatorial de segundo tumor primário em pacientes com carcinoma espinocelular primário de boca: estudo retrospectivo de 848 casos

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Tumor venéreo transmissível canino: critérios citológicos de malignidade e caracterização citomorfológica correlacionada a imunocitoquímica e lesões de DNA

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Tumor venéreo transmissível canino com enfoque nos diversos tratamentos

The canine Transmissible Venereal Tumor (TVT) is a neoplasm of round cells that primarily affects the external genitalia of both male and female dogs with high casuistry. Its transmission occurs by the tumor cells’ implementation in the mucous membranes during the coitus or in other body parts through licking, scratching or direct contact with the tumor. The clinical manifestations vary according to the location. Despite being a malignant neoplasm, TVT’s metastatic potential is low. The diagnosis is based on macroscopic characteristics, clinical signs, cytology and/or histopathology exam, among which cytology is considered the best method. There are several treatment protocols for the TVT, among which, surgical excision, radiotherapy, immunotherapy and chemotherapy. Chemotherapy with vincristine sulfate is the elected treatment. However, more and more new alternatives have been developed, as the usage of natural products, homeopathy and ivermectina. They can be used as a unique treatment to neoplasm or combined to the chemotherapy in order to decrease the dose and the application number of the chemotherapic and its side effects

Tumor odontogênico queratocístico e considerações diagnósticas

Keratocystic odontogenic tumor (KCOT is benign, featuring controversies in diagnosis and treatment. It occurs mainly in the region of the mandibular angle, which may or may not be related to a tooth and whose importance is due to its aggressive behavior and high recurrence rate. The causes of high rates of relapse observed in this lesion are dependent on factors such as age, location and size of lesion, gender, type of treatment and histological variant. The thin capsule and friable connective tissue of KCOT may favor the retention of epithelial debris responsible for the high proliferative capacity of this clinical entity. Due to the aggressiveness with its recurrence this paper aims to conduct a literature review addressing clinical and imaging aspects, composes the histopathological diagnosis of KCOT.